A Study of Ramucirumab (IMC-1121B) in Participants With Breast Cancer

Breast Cancer Clinical Trial

Official title:

A Phase 1b Study of Docetaxel in Combination With Ramucirumab (IMC-1121B) Drug Product in Patients With Locally Advanced or Metastatic Breast Cancer

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT01256567
• Other study ID #: 14200
• Secondary ID: CP12-1028I4T-IE-
• Status: Completed
• Phase: Phase 1
• First received: December 7, 2010
• Last updated: May 16, 2014
• Start date: December 2010
• Est. completion date: February 2013

Study information

• Verified date: May 2014
• Source: Eli Lilly and Company
• Contact: n/a
• Is FDA regulated: No
• Health authority: Japan: Institutional Review Board
• Study type: Interventional

Clinical Trial Summary

The primary objective of this study is to investigate the safety and tolerability of the anti-VEGFR-2 monoclonal antibody ramucirumab drug product in combination with docetaxel in Japanese participants with metastatic, or locally advanced breast cancer, with the aim of confirming the recommended dose of ramucirumab drug product (DP) in combination with docetaxel.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 7
• Est. completion date: February 2013
• Est. primary completion date: November 2012
• Accepts healthy volunteers: No
• Gender: Female
• Age group: 20 Years and older

Eligibility

Inclusion Criteria:

• The participant is Japanese

• The participant has an Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1

• The participant has a histopathologically or cytologically confirmed diagnosis of breast adenocarcinoma that is now metastatic or locally-recurrent and inoperable with curative intent

• The participant has measurable and/or non-measurable disease

• The participants' primary and/or metastatic tumor is Human Epidermal Growth Factor Receptor 2 (HER2) negative

• The participant received neo adjuvant or adjuvant taxane therapy = 6 months prior to the study

• The participant received neo adjuvant or adjuvant biologic therapy = 6 weeks prior to the study

• The participant completed all prior radiotherapy = 3 weeks prior to the study registration date

• The participant received prior hormonal therapy for breast cancer in the neo adjuvant, adjuvant,and/or the metastatic setting = 2 weeks prior to the study registration date

• The participant's left ventricular ejection fraction (LVEF) is within normal ranges

• The participant has adequate hematologic, hepatic, and coagulation function.

• Eligible participants of reproductive potential agree to use adequate contraceptive methods (hormonal or barrier methods) during the study period and for 12 weeks after the last dose of study medication

Exclusion Criteria:

• The participant has a concurrent active malignancy other than breast adenocarcinoma, adequately treated non-melanomatous skin cancer, or other non-invasive carcinoma or in situ neoplasm. Participants with previous treatment of malignancy is eligible, provided that she has been disease free for >3 years

• The participant has a known sensitivity to docetaxel

• The participant has a known sensitivity to agents of similar biologic composition as ramucirumab

• The participant has a history of chronic diarrheal disease within 6 months prior to the study registration date

• The participant has received irradiation to a major bone marrow area within 30 days prior to the study registration date

• The participant has received any experimental agents within 4 weeks prior to the study registration date

• The participant has a history of uncontrolled hereditary or acquired bleeding or thrombotic disorders

• The participant has Grade 3-4 bleeding within 3 months prior to the study registration date

• The participant has an ongoing or active infection requiring antibiotic, antifungal, or antiviral therapy

• The participant has uncontrolled hypertension, symptomatic congestive heart failure, psychiatric illness, or any other serious uncontrolled medical disorders

• The participant has brain metastases

• The participant has known human immunodeficiency virus infection or acquired immunodeficiency syndrome related illness

• The participant is pregnant or lactating

• The participant has not fully recovered from effects of prior chemotherapy

• The participant has undergone major surgery within 28 days prior to the study registration date

Study Design

Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment

Related Conditions & MeSH terms

• Breast Cancer
• Breast Neoplasms
• Metastatic Breast Cancer

Intervention

Biological:
• Ramucirumab
Ramucirumab administered as an intravenous (I.V.) infusion at a dose of 10 milligrams per kilogram (mg/kg) every 3 weeks.

Drug:
• Docetaxel
Docetaxel administered by intravenous (I.V.) infusion at a dose of 75 milligrams per square meter (mg/m^2) every 3 weeks.

Locations

Country	Name	City	State
Japan	ImClone Investigational Site	Hidaka
Japan	ImClone Investigational Site	Matsuyama
Japan	Imclone Investigational Site	Nagoya
Japan	ImClone Investigational Site	Osaka

Sponsors (1)

Lead Sponsor	Collaborator
Eli Lilly and Company

Country where clinical trial is conducted

Japan, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Number of Participants With Adverse Events	Number participants with drug related dose-limiting toxicities (DLT) during Cycle 1; ramucirumab related: treatment-emergent adverse events (TEAE), serious adverse events (SAE), Grade 3 or higher TEAE, or TEAE leading to discontinuation or ramucirumab dose modification. DLT=G4 neutropenia >7days; G =3 neutropenia with fever =38.5°C requiring IV antibiotics or bacteriemia or sepsis; G4 thrombocytopenia; G =3 thrombocytopenia with bleeding requiring platelets; G=3 prothrombin time and/or partial thromboplastin time in absence of anticoagulants; G=2 hyperbilirubinemia =5 days; QTc >500 milliseconds (ms) or increase =100 ms or arrhythmia; G=4 or uncontrollable hypertension; G=3 nonhematologic toxicity (excluding G3: hypersensitivity, injection-site reaction, arthralgia/myalgia, asthenia/fatigue, diarrhea without loperamide therapy, nausea/vomiting without antiemetics, transient G3/4 elevation of aminotransferases); treatment delay >2 weeks due to toxicity.	Baseline up to data cut off (approximately 48.3 weeks)	Yes
Secondary	Serum Anti-IMC-1121B Antibody Assessment (Immunogenicity)	The number of participants with a positive anti-IMC-1121B titer at any point during the study.	Baseline up to data cut off (approximately 48.3 weeks)	Yes
Secondary	Maximum Concentration (Cmax) of Ramucirumab	Cmax (Cycle 1) and Cmax at steady state (Cmax,ss, Cycle 4) of ramucirumab are provided.	Day 1 of Cycle 1 and Cycle 4 (cycle=21 days)	No
Secondary	Area Under the Curve (AUC) of Ramucirumab	AUC from time zero to infinity (AUC[0-inf], Cycle 1) and at steady state (AUC tau, Cycle 4) of ramucirumab are provided.	Day 1 of Cycles 1 and 4 (cycle=21 days)	No
Secondary	Half Life (t 1/2) of Ramucirumab		Day 1 of Cycles 1 and 4 (cycle=21 days)	No
Secondary	Clearance (Cl) of Ramucirumab	Clearance (Cycle 1) and at steady state (Clss, Cycle 4) of ramucirumab are provided.	Day 1 of Cycle 1 and Cycle 4 (cycle=21 days)	No
Secondary	Steady State Volume of Distribution (Vss) of Ramucirumab		Day 1 of Cycle 1 and 4 (cycle=21 days)	No